|
Synonyms: GNC-039 | GNC039
Compound class:
Antibody
Comment: Umizortamig (predicted to be GNC-039, from Systimmune's online pipeline page) is a tetra-specific antibody construct that was designed by the same pharma group as emfizatamab. The main difference between the two constructs is that umizortamig has a domain that recognises epidermal growth factor receptor variant III (EGFRvIII) in place of the CD19 binding domain of emfizatamab. The other 3 recognition domains are the same; CD3E, PD-L1 and 4-1BB (TNFRSF9). Umizortamig is intended to induce immunostimulatory and antineoplastic activities against tumours with the EGFRvIII variant. EGFRvIII is a gain-of-function mutation that arises from genomic deletion of exons 2-7 in the EGFR gene, and is a driver of a proportion of high-grade gliomas such as glioblastoma multiforme (GBM). It is likely that umizortamig is one of the so-called 'guidance and navigation control (GNC)' proteins that are claimed in Sichuan Baili Pharmaceutical/Systimmune patent US20210024630A1 [1].
|
Classification  |
|
| Compound class | Antibody |
| International Nonproprietary Names |
|
| INN number | INN |
| 12292 | umizortamig |
| Synonyms |
| GNC-039 | GNC039 |
| Database Links |
|
| GtoPdb PubChem SID | 472319300 |
| Search PubMed clinical trials | umizortamig |
| Search PubMed titles | umizortamig |
| Search PubMed titles/abstracts | umizortamig |
